AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26176640 — intervention group
Group type: EXPERIMENTAL
Intervention: E-mailing doctors online
Number of subjects: 406
Study 26176640 — intervention group
Group type: EXPERIMENTAL
Intervention: Willingness to e-mail doctors via a website
Number of subjects: 406
Study 26176640 — intervention group
Group type: EXPERIMENTAL
Intervention: Willingness to share medical information with doctors
Number of subjects: 406
Study 26176640 — intervention group
Group type: EXPERIMENTAL
Intervention: Willingness to send biological data to doctors
Number of subjects: 406
Study 26176640 — intervention group
Group type: EXPERIMENTAL
Intervention: Willingness to look at medical records online
Number of subjects: 406
Study 26176640 — intervention group
Group type: EXPERIMENTAL
Intervention: Willingness to track health conditions online
Number of subjects: 406
Study 26176640 — intervention group
Group type: EXPERIMENTAL
Intervention: Willingness to read about health conditions online
Number of subjects: 406
Study 26176640 — intervention group
Group type: EXPERIMENTAL
Intervention: Interest in sharing health information online with family members
Number of subjects: 406
Study 26176640 — intervention group
Group type: EXPERIMENTAL
Intervention: Interest in sharing health information for support groups
Number of subjects: 406
Study 23790699 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutch 10-session community occupational therapy programme
Number of subjects: 0
Study 23790699 — intervention group
Group type: COMPARATOR
Intervention: Control group (actively controlled)
Number of subjects: 0
Study 22041233 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-sterile pneumatic tourniquet
Number of subjects: 70
Study 22041233 — intervention group
Group type: COMPARATOR
Intervention: Sterile elastic exsanguination tourniquet (S-MART™)
Number of subjects: 70
Study 18079998 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-Lipoic acid (LA) supplementation with hyperbaric oxygen therapy (HBO)
Number of subjects: 0
Study 18079998 — intervention group
Group type: COMPARATOR
Intervention: Placebo with hyperbaric oxygen therapy (HBO)
Number of subjects: 0
Study 16583576 — intervention group
Group type: EXPERIMENTAL
Intervention: Savlon douching (1:1000 solution)
Number of subjects: 150
Study 16583576 — intervention group
Group type: COMPARATOR
Intervention: Povidone-iodine painting (1% solution)
Number of subjects: 150
Study 15497367 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotating stripes group (RS) - drum rotated at 5 rpm
Number of subjects: 48
Study 15497367 — intervention group
Group type: COMPARATOR
Intervention: Control group (Ctrl) - drum without stripes or rotation
Number of subjects: 48
Study 11204664 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic artery infusion alternating with systemic therapy (oxaliplatin and fluorouracil (5-FU) with leucovorin)
Number of subjects: 0
Study 11204664 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of oxaliplatin and fluorouracil (5-FU)
Number of subjects: 0
Study 9309270 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning administration of effervescent calcium carbasalate (ECC equivalent to 160 mg aspirin)
Number of subjects: 12
Study 9309270 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening administration of effervescent calcium carbasalate (ECC equivalent to 160 mg aspirin)
Number of subjects: 12
Study 9309270 — intervention group
Group type: EXPERIMENTAL
Intervention: Effervescent calcium carbasalate (ECC equivalent to 160 mg aspirin)
Number of subjects: 12
Study 8370289 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfluorocarbon‐associated gas exchange
Number of subjects: 11
Study 8370289 — intervention group
Group type: COMPARATOR
Intervention: Conventional mechanical ventilation
Number of subjects: 11
Study 3736281 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 mg Ro 17-1812
Number of subjects: 10
Study 3736281 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg Ro 17-1812
Number of subjects: 10
Study 3736281 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg Ro 17-1812
Number of subjects: 10
Study 3736281 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg diazepam
Number of subjects: 10
Study 3736281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31238116 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of Pseudomonas aeruginosa
Number of subjects: 22053
Study 31238116 — intervention group
Group type: EXPERIMENTAL
Intervention: Ever colonized with Pseudomonas aeruginosa
Number of subjects: 22053
Study 30853124 — intervention group
Group type: EXPERIMENTAL
Intervention: Buddy taping
Number of subjects: 97
Study 30853124 — intervention group
Group type: COMPARATOR
Intervention: Plaster casting
Number of subjects: 97
Study 28231946 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole 400 mg b.i.d.
Number of subjects: 120
Study 28231946 — intervention group
Group type: COMPARATOR
Intervention: Placebo 10 mg b.i.d.
Number of subjects: 120
Study 28231946 — intervention group
Group type: EXPERIMENTAL
Intervention: Benznidazole 200 mg + Posaconazole 400 mg b.i.d.
Number of subjects: 120
Study 28231946 — intervention group
Group type: EXPERIMENTAL
Intervention: Benznidazole 200 mg b.i.d.
Number of subjects: 120
Study 28231946 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole 400 mg b.i.d. (30 days)
Number of subjects: 120
Study 28231946 — intervention group
Group type: EXPERIMENTAL
Intervention: Benznidazole 200 mg b.i.d. (30 days)
Number of subjects: 120
Study 28231946 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole 400 mg b.i.d. (60 days)
Number of subjects: 120
Study 28231946 — intervention group
Group type: EXPERIMENTAL
Intervention: Benznidazole 200 mg b.i.d. (60 days)
Number of subjects: 120
Study 28231946 — intervention group
Group type: EXPERIMENTAL
Intervention: Benznidazole + Posaconazole (360 days)
Number of subjects: 120
Study 28231946 — intervention group
Group type: EXPERIMENTAL
Intervention: Benznidazole monotherapy (360 days)
Number of subjects: 120
Study 28231946 — intervention group
Group type: COMPARATOR
Intervention: Placebo (360 days)
Number of subjects: 120
Study 28231946 — intervention group
Group type: COMPARATOR
Intervention: Posaconazole (360 days)
Number of subjects: 120
Study 25880050 — intervention group
Group type: EXPERIMENTAL
Intervention: Low amplitude vibration (2 mm)
Number of subjects: 24
Study 25880050 — intervention group
Group type: EXPERIMENTAL
Intervention: High amplitude vibration (4 mm)
Number of subjects: 24
Study 24088749 — intervention group
Group type: EXPERIMENTAL
Intervention: sitagliptin + metformin
Number of subjects: 178
Study 24088749 — intervention group
Group type: COMPARATOR
Intervention: placebo + metformin
Number of subjects: 178
Study 21831722 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART program (Stress Management and Resiliency Training)
Number of subjects: 25
Study 21831722 — intervention group
Group type: COMPARATOR
Intervention: Control group (wait-list controlled)
Number of subjects: 25
Study 19624691 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute metabolic acidosis induced by administration of ammonium chloride (NH4Cl)
Number of subjects: 44
Study 19624691 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute metabolic acidosis induced by administration of ammonium chloride (NH4Cl) in COPD patients
Number of subjects: 44
Study 17251172 — intervention group
Group type: EXPERIMENTAL
Intervention: Power training (ballistic strength training)
Number of subjects: 21
Study 17251172 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance training (sensorimotor training [SMT])
Number of subjects: 21
Study 15266766 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Dose Femarelle (644 mg/day)
Number of subjects: 80
Study 15266766 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Dose Femarelle (344 mg/day)
Number of subjects: 80
Study 11497198 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (P) therapy
Number of subjects: 138
Study 11497198 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment (UC)
Number of subjects: 138
Study 9513582 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (72 micrograms)
Number of subjects: 15
Study 9513582 — intervention group
Group type: COMPARATOR
Intervention: Control (no ipratropium bromide)
Number of subjects: 15
Study 7508828 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 40 mg
Number of subjects: 31
Study 7508828 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 3067951 — intervention group
Group type: EXPERIMENTAL
Intervention: Human Actrapid (three times daily pre-prandial doses using a NovoPen) plus Human Ultratard (n = 19)
Number of subjects: 37
Study 3067951 — intervention group
Group type: COMPARATOR
Intervention: Premixed insulin (n = 18)
Number of subjects: 37
Study 31000566 — intervention group
Group type: EXPERIMENTAL
Intervention: Default session duration of 4.25 hours (255 minutes) for incident patients
Number of subjects: 7035
Study 31000566 — intervention group
Group type: COMPARATOR
Intervention: Usual care with no trial-driven approach to session duration
Number of subjects: 7035
Study 27543905 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tocopherol acetate
Number of subjects: 34
Study 27543905 — intervention group
Group type: COMPARATOR
Intervention: Placebo (liquid paraffin)
Number of subjects: 34
Study 25534576 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide 150 mg/m² days 1-7 and 15-21, every 28 days for 8 cycles
Number of subjects: 62
Study 23496992 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate recommendation to quit (addition to standard care)
Number of subjects: 0
Study 23496992 — intervention group
Group type: EXPERIMENTAL
Intervention: Encouragement to structured planning (addition to standard care)
Number of subjects: 0
Study 23496992 — intervention group
Group type: COMPARATOR
Intervention: Standard care (QuitCoach)
Number of subjects: 0
Study 21546875 — intervention group
Group type: EXPERIMENTAL
Intervention: Bethanechol chloride (Ucholine 20 mg 3 times a day on the third to seventh postoperative day)
Number of subjects: 62
Study 21546875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 18266878 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic bacteria
Number of subjects: 0
Study 18266878 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16434866 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin-azithromycin combined triple therapy (omeprazole 20 mg bid, levofloxacin 500 mg od, azithromycin 500 mg od) for 7 days
Number of subjects: 137
Study 16434866 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin-azithromycin combined triple therapy for second-line eradication
Number of subjects: 137
Study 16434866 — intervention group
Group type: COMPARATOR
Intervention: Standard PPI-based triple therapy (omeprazole 20 mg bid, amoxicillin 1.0 g bid, clarithromycin 500 mg bid) for 7 days
Number of subjects: 137
Study 16434866 — intervention group
Group type: COMPARATOR
Intervention: Bismuth-based quadruple therapy (omeprazole 20 mg bid, bismuth 120 mg qid, metronidazole 500 mg tid, tetracycline 500 mg qid) for second-line eradication
Number of subjects: 137
Study 12606508 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone (600 mg/day, n = 4)
Number of subjects: 26
Study 12606508 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (approximately 2,000 mg/day, n = 8)
Number of subjects: 26
Study 12606508 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 8)
Number of subjects: 26
Study 12606508 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (n = 6)
Number of subjects: 26
Study 11111610 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone Reassurance Programme (TRP)
Number of subjects: 0
Study 11111610 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TRP)
Number of subjects: 0
Study 9126512 — intervention group
Group type: EXPERIMENTAL
Intervention: Winter season responses for 13-14 year olds (asthma questionnaire)
Number of subjects: 21437
Study 9126512 — intervention group
Group type: EXPERIMENTAL
Intervention: Winter season responses for video questionnaire (asthma symptoms)
Number of subjects: 21437
Study 9126512 — intervention group
Group type: EXPERIMENTAL
Intervention: Responses to rhinitis symptoms (both age groups)
Number of subjects: 21437
Study 9126512 — intervention group
Group type: EXPERIMENTAL
Intervention: Responses to eczema questions
Number of subjects: 21437
Study 9126512 — intervention group
Group type: EXPERIMENTAL
Intervention: Responses to asthma questions (6-7 year olds)
Number of subjects: 21437
Study 8469319 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta-1b (IFNB)
Number of subjects: 372
Study 8469319 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 372
Study 6375145 — intervention group
Group type: EXPERIMENTAL
Intervention: Static magnetic fields applied using energy pak foils
Number of subjects: 0
Study 6375145 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 30642773 — intervention group
Group type: EXPERIMENTAL
Intervention: Step-wise mobility protocol
Number of subjects: 56
Study 29490071 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone Disclosure (TD)
Number of subjects: 1178
Study 29490071 — intervention group
Group type: COMPARATOR
Intervention: In-Person Disclosure (IPD)
Number of subjects: 1178
Study 27383095 — intervention group
Group type: EXPERIMENTAL
Intervention: Entrepreneurship education program
Number of subjects: 0
Study 23992673 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 100
Study 23992673 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 19922514 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette deprivation (abstaining from smoking for 24 hours)
Number of subjects: 101
Study 19922514 — intervention group
Group type: COMPARATOR
Intervention: Cigarette availability (continuing to smoke regular amount)
Number of subjects: 101
Study 19922514 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to cigarette cues
Number of subjects: 101
Study 19922514 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing availability of cigarette cues
Number of subjects: 101
Study 19922514 — intervention group
Group type: EXPERIMENTAL
Intervention: Deprivation
Number of subjects: 101
Study 19922514 — intervention group
Group type: COMPARATOR
Intervention: High cigarette availability
Number of subjects: 101
Study 16245220 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (600 IU/day) plus Vitamin C (500 mg/day)
Number of subjects: 57
Study 16245220 — intervention group
Group type: COMPARATOR
Intervention: Ursodeoxycholic acid (10 mg/kg/day)
Number of subjects: 57
Study 11428471 — intervention group
Group type: EXPERIMENTAL
Intervention: Reused catheter
Number of subjects: 377
Study 11428471 — intervention group
Group type: COMPARATOR
Intervention: New catheter
Number of subjects: 377
Study 9588606 — intervention group
Group type: EXPERIMENTAL
Intervention: Protonics device during activities of daily living (ADL)
Number of subjects: 100
Study 9588606 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 100
Study 7518020 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (2 cycles of cis-platinum 100 mg/m2, bleomycin 10 mg/m2 loading dose, followed by 10 mg/m2/day continuous infusion, and vinblastine 3 mg/m2)
Number of subjects: 46
Study 7518020 — intervention group
Group type: COMPARATOR
Intervention: Control group (surgery alone)
Number of subjects: 46
Study 7518020 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy group
Number of subjects: 46
Study 2609062 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% DMSO gel
Number of subjects: 20
Study 2609062 — intervention group
Group type: COMPARATOR
Intervention: Placebo (glycerol)
Number of subjects: 20
Study 9295 — intervention group
Group type: EXPERIMENTAL
Intervention: Clenbuterol (10 mug 3 times a day)
Number of subjects: 19
Study 9295 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (4 mg 3 times a day)
Number of subjects: 19
Study 9295 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 9295 — intervention group
Group type: EXPERIMENTAL
Intervention: Clenbuterol and Salbutamol
Number of subjects: 19
Study 30646129 — intervention group
Group type: EXPERIMENTAL
Intervention: Primaquine treatment (high-dose)
Number of subjects: 57
Study 30646129 — intervention group
Group type: COMPARATOR
Intervention: Control (no primaquine treatment)
Number of subjects: 57
Study 27225043 — intervention group
Group type: EXPERIMENTAL
Intervention: i-Walker robotic training
Number of subjects: 44
Study 23804431 — intervention group
Group type: EXPERIMENTAL
Intervention: Triplets Prediction Task (TPT)
Number of subjects: 0
Study 22126366 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 × 35 s maximal static exercise
Number of subjects: 20
Study 20044198 — intervention group
Group type: EXPERIMENTAL
Intervention: Layperson CPR
Number of subjects: 26
Study 18702803 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual physical activity counseling (4 sessions)
Number of subjects: 224
Study 18702803 — intervention group
Group type: COMPARATOR
Intervention: Control group (former practices with brief PA advice)
Number of subjects: 224
Study 16171660 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 40
Study 16171660 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 40
Study 12699135 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 28
Study 12699135 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 28
Study 10372711 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐T4 substitutive therapy (mean dose, 68 microg daily)
Number of subjects: 26
Study 10372711 — intervention group
Group type: COMPARATOR
Intervention: Control group (30 subjects matched for age, sex, and body surface area)
Number of subjects: 26
Study 10372711 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with subclinical hypothyroidism (before treatment)
Number of subjects: 26
Study 8894205 — intervention group
Group type: EXPERIMENTAL
Intervention: MHI-5
Number of subjects: 3000
Study 8894205 — intervention group
Group type: EXPERIMENTAL
Intervention: GHQ-12
Number of subjects: 3000
Study 8894205 — intervention group
Group type: COMPARATOR
Intervention: Both instruments
Number of subjects: 3000
Study 2051004 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 41
Study 2051004 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 6861770 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg b.i.d.
Number of subjects: 10
Study 6861770 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg b.i.d.
Number of subjects: 10
Study 6861770 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31498415 — intervention group
Group type: EXPERIMENTAL
Intervention: Topography-guided customized ablation treatment (TCAT)
Number of subjects: 216
Study 31498415 — intervention group
Group type: COMPARATOR
Intervention: Wavefront-optimized (WFO) LASIK
Number of subjects: 216
Study 29582053 — intervention group
Group type: EXPERIMENTAL
Intervention: AAV2-NGF
Number of subjects: 49
Study 29582053 — intervention group
Group type: COMPARATOR
Intervention: Sham surgery
Number of subjects: 49
Study 26963483 — intervention group
Group type: EXPERIMENTAL
Intervention: Branched-chain amino acids (BCAAs) 6 g consumed 10 min before exercise and exercise therapy (twice weekly for 3 months)
Number of subjects: 0
Study 26963483 — intervention group
Group type: COMPARATOR
Intervention: Control group (maltodextrin 6 g consumed 10 min before exercise and exercise therapy)
Number of subjects: 0
Study 26963483 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAAs administration
Number of subjects: 0
Study 26963483 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of BCAA intake and exercise therapy
Number of subjects: 0
Study 24913837 — intervention group
Group type: EXPERIMENTAL
Intervention: Effortful swallows preceded by high-effort sips from small-diameter straws
Number of subjects: 40
Study 24913837 — intervention group
Group type: EXPERIMENTAL
Intervention: Effortful swallows preceded by maximum effort lingual elevation
Number of subjects: 40
Study 24913837 — intervention group
Group type: EXPERIMENTAL
Intervention: Effortful swallows performed in isolation
Number of subjects: 40
Study 24913837 — intervention group
Group type: COMPARATOR
Intervention: Noneffortful swallows
Number of subjects: 40
Study 22981891 — intervention group
Group type: EXPERIMENTAL
Intervention: 21-gene profile
Number of subjects: 0
Study 22981891 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 20101752 — intervention group
Group type: EXPERIMENTAL
Intervention: Ishak fibrosis stage 2
Number of subjects: 1050
Study 20101752 — intervention group
Group type: EXPERIMENTAL
Intervention: Ishak fibrosis stage 3
Number of subjects: 1050
Study 20101752 — intervention group
Group type: EXPERIMENTAL
Intervention: Ishak fibrosis stage 4
Number of subjects: 1050
Study 20101752 — intervention group
Group type: EXPERIMENTAL
Intervention: Ishak fibrosis stage 5
Number of subjects: 1050
Study 20101752 — intervention group
Group type: EXPERIMENTAL
Intervention: Ishak fibrosis stage 6
Number of subjects: 1050
Study 20101752 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonfragmented biopsy specimens
Number of subjects: 1050
Study 20101752 — intervention group
Group type: EXPERIMENTAL
Intervention: Fragmented biopsy specimens
Number of subjects: 1050
Study 20101752 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver transplantation or liver-related death
Number of subjects: 1050
Study 18060212 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac sodium 150 mg/day
Number of subjects: 100
Study 18060212 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 1500 mg/day
Number of subjects: 100
Study 18060212 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 18060212 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac sodium
Number of subjects: 100
Study 16264047 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment including bosentan, sildenafil, and inhaled iloprost
Number of subjects: 123
Study 16264047 — intervention group
Group type: COMPARATOR
Intervention: Historical control group
Number of subjects: 123
Study 12133040 — intervention group
Group type: EXPERIMENTAL
Intervention: eletriptan 20 mg
Number of subjects: 402
Study 12133040 — intervention group
Group type: EXPERIMENTAL
Intervention: eletriptan 40 mg
Number of subjects: 402
Study 12133040 — intervention group
Group type: EXPERIMENTAL
Intervention: eletriptan 80 mg
Number of subjects: 402